Literature DB >> 8558057

Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation.

J M Schröder1, N Noso, M Sticherling, E Christophers.   

Abstract

In the dermal sites of atopic skin, eosinophil (Eo) granule protein or more rarely intact Eos represent a characteristic histological feature. We addressed the question of whether lesional scales of patients with various eosinophilic skin disorders contain Eo attractant and tried to characterize it biochemically. In scales of a patient with drug reaction, heparin-binding Eo attractants could be identified. High-performance liquid chromatographic analyses together with specific ELISA and Western blot analyses revealed identity with RANTES. No other heparin-binding Eo chemotaxin could be identified. HPLC analysis of pooled lesional scale extracts of patients with atopic dermatitis showed fractions containing only weak heparin-binding Eo-chemotactic activity, which, however, showed RANTES immunoreactivity. In experiments to elucidate the putative cellular origin of Eo-attracting chemokines in human skin we investigated supernatants of atopic skin we investigated supernatants of atopic skin-derived T lymphocytes as well as supernatants of stimulated dermal fibroblasts for Eo-chemotactic factors. Unexpectedly, we did not find any heparin-bound Eo attractants in supernatants of stimulated cultured atopic skin-derived T lymphocyte clones, whereas fibroblasts produced RANTES as well as granulocyte-macrophage colony-stimulating factor. Therefore, fibroblasts are likely source of eosinophil attractant cells, which could contribute to the Eo infiltrate. Selectivity of the infiltrate might come from selective induction of RANTES and/or induction of other as yet unidentified Eo-specific chemokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558057

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD).

Authors:  Y Hatano; K Katagiri; S Takayasu
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis.

Authors:  Zahra Ahmadi; Gholamhossein Hassanshahi; Hossein Khorramdelazad; Nahid Zainodini; Leila Koochakzadeh
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3.

Authors:  Jongsung Lee; Eunsun Jung; Youngji Kim; Jiyoung Lee; Junho Park; Seongtaek Hong; Chang-Gu Hyun; Deokhoon Park; Yeong Shik Kim
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

4.  CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.

Authors:  Weilie Ma; Paul J Bryce; Alison A Humbles; Dhafer Laouini; Ali Yalcindag; Harri Alenius; Daniel S Friend; Hans C Oettgen; Craig Gerard; Raif S Geha
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

5.  Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions.

Authors:  A A Kirkaldy; A C Musonda; S Khanolkhar-Young; S Suneetha; D N J Lockwood
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

6.  Mechanisms underlying the inhibitory effects of tachykinin receptor antagonists on eosinophil recruitment in an allergic pleurisy model in mice.

Authors:  Ana Leticia Alessandri; Vanessa Pinho; Danielle G Souza; Maria Salete de A Castro; Andre Klein; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2003-11       Impact factor: 8.739

Review 7.  Cellular aspects of atopic dermatitis.

Authors:  Liang-Shiou Ou; Jing-Long Huang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.